Loading…

MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases

In primary melanoma, ETV1 transcription factor was suggested to be activated mainly by gene amplification and to promote tumor growth in cooperation with BRAF (V600E) . Aim of this study was to investigate ETV1 expression in human melanoma with a focus on brain metastases. We investigated ETV1 in 68...

Full description

Saved in:
Bibliographic Details
Published in:Archives of dermatological research 2014-12, Vol.306 (10), p.873-884
Main Authors: Birner, Peter, Berghoff, Anna S, Dinhof, Carina, Pirker, Christine, Capper, David, Schoppmann, Sebastian F, Petzelbauer, Peter, von Deimling, Andreas, Berger, Walter, Preusser, Matthias
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 884
container_issue 10
container_start_page 873
container_title Archives of dermatological research
container_volume 306
creator Birner, Peter
Berghoff, Anna S
Dinhof, Carina
Pirker, Christine
Capper, David
Schoppmann, Sebastian F
Petzelbauer, Peter
von Deimling, Andreas
Berger, Walter
Preusser, Matthias
description In primary melanoma, ETV1 transcription factor was suggested to be activated mainly by gene amplification and to promote tumor growth in cooperation with BRAF (V600E) . Aim of this study was to investigate ETV1 expression in human melanoma with a focus on brain metastases. We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 gene (located at chromosome 7p21) and centromere chromosome 7 and immunohistochemistry for ETV1, BRAF (V600E) , and ETV1/BRAF associated proteins pMSK1, pRSK1, pp38, pMEK1/2, MAPKAP kinase 2, CIC, HIF-1alpha and Ki-67. We further studied ETV1 copy number variations in 32 melanoma cell lines from primary and metastatic lesions using array CGH. The influence of the MAP kinase pathway activity on ETV1 mRNA and protein expression under BRAF wild-type and BRAF (V600E) conditions were determined in melanoma cell lines using qRT-PCR and Western Blot. No ETV1 high grade amplifications were observed in tissue samples, but low grade ETV1 gene amplifications were found in 7 (10.3 %) melanoma brain metastases. ETV1 protein expression in tissue samples (15 %) correlated with BRAF (V600E) status (p = 0.007) and HIF-1alpha expression (p = 0.049), but not with ETV1 gene dose. Application of the BRAF(V600E)-specific inhibitor vemurafenib and the BRAF(V6ooE/V600K)-inhibitor dabrafenib revealed predominant regulation of ETV-1 mRNA and protein via MAPK-pathway. ETV1 expression is a rare event in human melanoma and seems to be rather based on hyperactivation of MAPK signals, by BRAF (V600E) mutation, than on ETV1 gene amplification. Consequently, therapeutic inhibition of BRAF and the downstream MAPK pathway also down-regulates oncogenic ETV1 expression.
doi_str_mv 10.1007/s00403-014-1490-6
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1625343333</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1625343333</sourcerecordid><originalsourceid>FETCH-LOGICAL-p281t-b20623755970ba54310b104db2f14aa590e03902e1ae778c5926d07ed2cbacb63</originalsourceid><addsrcrecordid>eNo1kNtOAkEMhicmRhB9AG_MXOLFauewu-wlElATjMYg8Y50douMsgd3ZlUexPd1QWyaNH_69U9bxs4EXAqA-MoBaFABCB0InUAQHbCu0EoGECUvHXbs3Bu0XDwQR6wjQ4hVDLrLfu6Hj_zdFuiIY-rtp_Ub7pqqKmtPGTcbfv00nPD-PAIYX_C88ehtWfAa_Ypq7ldY8Fcq2uG8WtulTf_a1nF0rkwtbl2-rF_x8WwuOH1XNTm3Qwqe0xqLMkduatxJj65NcifscIlrR6f72mPPk_FsdBtMH27uRsNpUMmB8IGREEkVh2ESg8FQKwFGgM6MXAqNGCZAoBKQJJDay9MwkVEGMWUyNZiaSPVY_8-3qsuPhpxf5NaltG7XorJxCxHJUGm1jR4736ONySlbVLXNsd4s_l-pfgGmQnTA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1625343333</pqid></control><display><type>article</type><title>MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases</title><source>Springer Link</source><creator>Birner, Peter ; Berghoff, Anna S ; Dinhof, Carina ; Pirker, Christine ; Capper, David ; Schoppmann, Sebastian F ; Petzelbauer, Peter ; von Deimling, Andreas ; Berger, Walter ; Preusser, Matthias</creator><creatorcontrib>Birner, Peter ; Berghoff, Anna S ; Dinhof, Carina ; Pirker, Christine ; Capper, David ; Schoppmann, Sebastian F ; Petzelbauer, Peter ; von Deimling, Andreas ; Berger, Walter ; Preusser, Matthias</creatorcontrib><description>In primary melanoma, ETV1 transcription factor was suggested to be activated mainly by gene amplification and to promote tumor growth in cooperation with BRAF (V600E) . Aim of this study was to investigate ETV1 expression in human melanoma with a focus on brain metastases. We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 gene (located at chromosome 7p21) and centromere chromosome 7 and immunohistochemistry for ETV1, BRAF (V600E) , and ETV1/BRAF associated proteins pMSK1, pRSK1, pp38, pMEK1/2, MAPKAP kinase 2, CIC, HIF-1alpha and Ki-67. We further studied ETV1 copy number variations in 32 melanoma cell lines from primary and metastatic lesions using array CGH. The influence of the MAP kinase pathway activity on ETV1 mRNA and protein expression under BRAF wild-type and BRAF (V600E) conditions were determined in melanoma cell lines using qRT-PCR and Western Blot. No ETV1 high grade amplifications were observed in tissue samples, but low grade ETV1 gene amplifications were found in 7 (10.3 %) melanoma brain metastases. ETV1 protein expression in tissue samples (15 %) correlated with BRAF (V600E) status (p = 0.007) and HIF-1alpha expression (p = 0.049), but not with ETV1 gene dose. Application of the BRAF(V600E)-specific inhibitor vemurafenib and the BRAF(V6ooE/V600K)-inhibitor dabrafenib revealed predominant regulation of ETV-1 mRNA and protein via MAPK-pathway. ETV1 expression is a rare event in human melanoma and seems to be rather based on hyperactivation of MAPK signals, by BRAF (V600E) mutation, than on ETV1 gene amplification. Consequently, therapeutic inhibition of BRAF and the downstream MAPK pathway also down-regulates oncogenic ETV1 expression.</description><identifier>EISSN: 1432-069X</identifier><identifier>DOI: 10.1007/s00403-014-1490-6</identifier><identifier>PMID: 25073704</identifier><language>eng</language><publisher>Germany</publisher><subject>Adult ; Aged ; Brain Neoplasms - enzymology ; Brain Neoplasms - genetics ; Brain Neoplasms - mortality ; Brain Neoplasms - secondary ; Cell Line, Tumor ; DNA Copy Number Variations ; DNA-Binding Proteins - genetics ; DNA-Binding Proteins - metabolism ; Female ; Gene Dosage ; Gene Expression Regulation, Neoplastic ; Humans ; Imidazoles - pharmacology ; Indoles - pharmacology ; Male ; Melanoma - enzymology ; Melanoma - genetics ; Melanoma - mortality ; Melanoma - secondary ; Middle Aged ; Mitogen-Activated Protein Kinases - metabolism ; Mutation ; Oximes - pharmacology ; Prognosis ; Proportional Hazards Models ; Protein Kinase Inhibitors - pharmacology ; Proto-Oncogene Proteins B-raf - antagonists &amp; inhibitors ; Proto-Oncogene Proteins B-raf - genetics ; Proto-Oncogene Proteins B-raf - metabolism ; RNA, Messenger - metabolism ; Signal Transduction - drug effects ; Skin Neoplasms - enzymology ; Skin Neoplasms - genetics ; Skin Neoplasms - mortality ; Skin Neoplasms - pathology ; Sulfonamides - pharmacology ; Time Factors ; Transcription Factors - genetics ; Transcription Factors - metabolism</subject><ispartof>Archives of dermatological research, 2014-12, Vol.306 (10), p.873-884</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25073704$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Birner, Peter</creatorcontrib><creatorcontrib>Berghoff, Anna S</creatorcontrib><creatorcontrib>Dinhof, Carina</creatorcontrib><creatorcontrib>Pirker, Christine</creatorcontrib><creatorcontrib>Capper, David</creatorcontrib><creatorcontrib>Schoppmann, Sebastian F</creatorcontrib><creatorcontrib>Petzelbauer, Peter</creatorcontrib><creatorcontrib>von Deimling, Andreas</creatorcontrib><creatorcontrib>Berger, Walter</creatorcontrib><creatorcontrib>Preusser, Matthias</creatorcontrib><title>MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases</title><title>Archives of dermatological research</title><addtitle>Arch Dermatol Res</addtitle><description>In primary melanoma, ETV1 transcription factor was suggested to be activated mainly by gene amplification and to promote tumor growth in cooperation with BRAF (V600E) . Aim of this study was to investigate ETV1 expression in human melanoma with a focus on brain metastases. We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 gene (located at chromosome 7p21) and centromere chromosome 7 and immunohistochemistry for ETV1, BRAF (V600E) , and ETV1/BRAF associated proteins pMSK1, pRSK1, pp38, pMEK1/2, MAPKAP kinase 2, CIC, HIF-1alpha and Ki-67. We further studied ETV1 copy number variations in 32 melanoma cell lines from primary and metastatic lesions using array CGH. The influence of the MAP kinase pathway activity on ETV1 mRNA and protein expression under BRAF wild-type and BRAF (V600E) conditions were determined in melanoma cell lines using qRT-PCR and Western Blot. No ETV1 high grade amplifications were observed in tissue samples, but low grade ETV1 gene amplifications were found in 7 (10.3 %) melanoma brain metastases. ETV1 protein expression in tissue samples (15 %) correlated with BRAF (V600E) status (p = 0.007) and HIF-1alpha expression (p = 0.049), but not with ETV1 gene dose. Application of the BRAF(V600E)-specific inhibitor vemurafenib and the BRAF(V6ooE/V600K)-inhibitor dabrafenib revealed predominant regulation of ETV-1 mRNA and protein via MAPK-pathway. ETV1 expression is a rare event in human melanoma and seems to be rather based on hyperactivation of MAPK signals, by BRAF (V600E) mutation, than on ETV1 gene amplification. Consequently, therapeutic inhibition of BRAF and the downstream MAPK pathway also down-regulates oncogenic ETV1 expression.</description><subject>Adult</subject><subject>Aged</subject><subject>Brain Neoplasms - enzymology</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - secondary</subject><subject>Cell Line, Tumor</subject><subject>DNA Copy Number Variations</subject><subject>DNA-Binding Proteins - genetics</subject><subject>DNA-Binding Proteins - metabolism</subject><subject>Female</subject><subject>Gene Dosage</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>Imidazoles - pharmacology</subject><subject>Indoles - pharmacology</subject><subject>Male</subject><subject>Melanoma - enzymology</subject><subject>Melanoma - genetics</subject><subject>Melanoma - mortality</subject><subject>Melanoma - secondary</subject><subject>Middle Aged</subject><subject>Mitogen-Activated Protein Kinases - metabolism</subject><subject>Mutation</subject><subject>Oximes - pharmacology</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Proto-Oncogene Proteins B-raf - antagonists &amp; inhibitors</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Proto-Oncogene Proteins B-raf - metabolism</subject><subject>RNA, Messenger - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Skin Neoplasms - enzymology</subject><subject>Skin Neoplasms - genetics</subject><subject>Skin Neoplasms - mortality</subject><subject>Skin Neoplasms - pathology</subject><subject>Sulfonamides - pharmacology</subject><subject>Time Factors</subject><subject>Transcription Factors - genetics</subject><subject>Transcription Factors - metabolism</subject><issn>1432-069X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNo1kNtOAkEMhicmRhB9AG_MXOLFauewu-wlElATjMYg8Y50douMsgd3ZlUexPd1QWyaNH_69U9bxs4EXAqA-MoBaFABCB0InUAQHbCu0EoGECUvHXbs3Bu0XDwQR6wjQ4hVDLrLfu6Hj_zdFuiIY-rtp_Ub7pqqKmtPGTcbfv00nPD-PAIYX_C88ehtWfAa_Ypq7ldY8Fcq2uG8WtulTf_a1nF0rkwtbl2-rF_x8WwuOH1XNTm3Qwqe0xqLMkduatxJj65NcifscIlrR6f72mPPk_FsdBtMH27uRsNpUMmB8IGREEkVh2ESg8FQKwFGgM6MXAqNGCZAoBKQJJDay9MwkVEGMWUyNZiaSPVY_8-3qsuPhpxf5NaltG7XorJxCxHJUGm1jR4736ONySlbVLXNsd4s_l-pfgGmQnTA</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Birner, Peter</creator><creator>Berghoff, Anna S</creator><creator>Dinhof, Carina</creator><creator>Pirker, Christine</creator><creator>Capper, David</creator><creator>Schoppmann, Sebastian F</creator><creator>Petzelbauer, Peter</creator><creator>von Deimling, Andreas</creator><creator>Berger, Walter</creator><creator>Preusser, Matthias</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20141201</creationdate><title>MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases</title><author>Birner, Peter ; Berghoff, Anna S ; Dinhof, Carina ; Pirker, Christine ; Capper, David ; Schoppmann, Sebastian F ; Petzelbauer, Peter ; von Deimling, Andreas ; Berger, Walter ; Preusser, Matthias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p281t-b20623755970ba54310b104db2f14aa590e03902e1ae778c5926d07ed2cbacb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Brain Neoplasms - enzymology</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - secondary</topic><topic>Cell Line, Tumor</topic><topic>DNA Copy Number Variations</topic><topic>DNA-Binding Proteins - genetics</topic><topic>DNA-Binding Proteins - metabolism</topic><topic>Female</topic><topic>Gene Dosage</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>Imidazoles - pharmacology</topic><topic>Indoles - pharmacology</topic><topic>Male</topic><topic>Melanoma - enzymology</topic><topic>Melanoma - genetics</topic><topic>Melanoma - mortality</topic><topic>Melanoma - secondary</topic><topic>Middle Aged</topic><topic>Mitogen-Activated Protein Kinases - metabolism</topic><topic>Mutation</topic><topic>Oximes - pharmacology</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Proto-Oncogene Proteins B-raf - antagonists &amp; inhibitors</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Proto-Oncogene Proteins B-raf - metabolism</topic><topic>RNA, Messenger - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Skin Neoplasms - enzymology</topic><topic>Skin Neoplasms - genetics</topic><topic>Skin Neoplasms - mortality</topic><topic>Skin Neoplasms - pathology</topic><topic>Sulfonamides - pharmacology</topic><topic>Time Factors</topic><topic>Transcription Factors - genetics</topic><topic>Transcription Factors - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Birner, Peter</creatorcontrib><creatorcontrib>Berghoff, Anna S</creatorcontrib><creatorcontrib>Dinhof, Carina</creatorcontrib><creatorcontrib>Pirker, Christine</creatorcontrib><creatorcontrib>Capper, David</creatorcontrib><creatorcontrib>Schoppmann, Sebastian F</creatorcontrib><creatorcontrib>Petzelbauer, Peter</creatorcontrib><creatorcontrib>von Deimling, Andreas</creatorcontrib><creatorcontrib>Berger, Walter</creatorcontrib><creatorcontrib>Preusser, Matthias</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of dermatological research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Birner, Peter</au><au>Berghoff, Anna S</au><au>Dinhof, Carina</au><au>Pirker, Christine</au><au>Capper, David</au><au>Schoppmann, Sebastian F</au><au>Petzelbauer, Peter</au><au>von Deimling, Andreas</au><au>Berger, Walter</au><au>Preusser, Matthias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases</atitle><jtitle>Archives of dermatological research</jtitle><addtitle>Arch Dermatol Res</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>306</volume><issue>10</issue><spage>873</spage><epage>884</epage><pages>873-884</pages><eissn>1432-069X</eissn><abstract>In primary melanoma, ETV1 transcription factor was suggested to be activated mainly by gene amplification and to promote tumor growth in cooperation with BRAF (V600E) . Aim of this study was to investigate ETV1 expression in human melanoma with a focus on brain metastases. We investigated ETV1 in 68 human melanoma brain metastases using FISH for ETV1 gene (located at chromosome 7p21) and centromere chromosome 7 and immunohistochemistry for ETV1, BRAF (V600E) , and ETV1/BRAF associated proteins pMSK1, pRSK1, pp38, pMEK1/2, MAPKAP kinase 2, CIC, HIF-1alpha and Ki-67. We further studied ETV1 copy number variations in 32 melanoma cell lines from primary and metastatic lesions using array CGH. The influence of the MAP kinase pathway activity on ETV1 mRNA and protein expression under BRAF wild-type and BRAF (V600E) conditions were determined in melanoma cell lines using qRT-PCR and Western Blot. No ETV1 high grade amplifications were observed in tissue samples, but low grade ETV1 gene amplifications were found in 7 (10.3 %) melanoma brain metastases. ETV1 protein expression in tissue samples (15 %) correlated with BRAF (V600E) status (p = 0.007) and HIF-1alpha expression (p = 0.049), but not with ETV1 gene dose. Application of the BRAF(V600E)-specific inhibitor vemurafenib and the BRAF(V6ooE/V600K)-inhibitor dabrafenib revealed predominant regulation of ETV-1 mRNA and protein via MAPK-pathway. ETV1 expression is a rare event in human melanoma and seems to be rather based on hyperactivation of MAPK signals, by BRAF (V600E) mutation, than on ETV1 gene amplification. Consequently, therapeutic inhibition of BRAF and the downstream MAPK pathway also down-regulates oncogenic ETV1 expression.</abstract><cop>Germany</cop><pmid>25073704</pmid><doi>10.1007/s00403-014-1490-6</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1432-069X
ispartof Archives of dermatological research, 2014-12, Vol.306 (10), p.873-884
issn 1432-069X
language eng
recordid cdi_proquest_miscellaneous_1625343333
source Springer Link
subjects Adult
Aged
Brain Neoplasms - enzymology
Brain Neoplasms - genetics
Brain Neoplasms - mortality
Brain Neoplasms - secondary
Cell Line, Tumor
DNA Copy Number Variations
DNA-Binding Proteins - genetics
DNA-Binding Proteins - metabolism
Female
Gene Dosage
Gene Expression Regulation, Neoplastic
Humans
Imidazoles - pharmacology
Indoles - pharmacology
Male
Melanoma - enzymology
Melanoma - genetics
Melanoma - mortality
Melanoma - secondary
Middle Aged
Mitogen-Activated Protein Kinases - metabolism
Mutation
Oximes - pharmacology
Prognosis
Proportional Hazards Models
Protein Kinase Inhibitors - pharmacology
Proto-Oncogene Proteins B-raf - antagonists & inhibitors
Proto-Oncogene Proteins B-raf - genetics
Proto-Oncogene Proteins B-raf - metabolism
RNA, Messenger - metabolism
Signal Transduction - drug effects
Skin Neoplasms - enzymology
Skin Neoplasms - genetics
Skin Neoplasms - mortality
Skin Neoplasms - pathology
Sulfonamides - pharmacology
Time Factors
Transcription Factors - genetics
Transcription Factors - metabolism
title MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A36%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MAP%20kinase%20activity%20supported%20by%20BRAF%20(V600E)%20mutation%20rather%20than%20gene%20amplification%20is%20associated%20with%20ETV1%20expression%20in%20melanoma%20brain%20metastases&rft.jtitle=Archives%20of%20dermatological%20research&rft.au=Birner,%20Peter&rft.date=2014-12-01&rft.volume=306&rft.issue=10&rft.spage=873&rft.epage=884&rft.pages=873-884&rft.eissn=1432-069X&rft_id=info:doi/10.1007/s00403-014-1490-6&rft_dat=%3Cproquest_pubme%3E1625343333%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p281t-b20623755970ba54310b104db2f14aa590e03902e1ae778c5926d07ed2cbacb63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1625343333&rft_id=info:pmid/25073704&rfr_iscdi=true